GLP-1 agonists

How to Assess Second-Line Diabetes Agents for Patients at Risk for Major Osteoporotic Fractures

What are the best ways to help prevent your type 2 diabetes patient avoid major osteoporotic fractures many diabetes medications can actually increase the risk of fracture? This interactive case study features can exploration of current science, clinical recommendations and medication options. The case study provides insights into mitigating fracture risk while effectively treating type 2 diabetes.

How would you care for this diabetes patient who survived a heart attack?

Earn up to 0.5 AMA PRA Category 1 CME credits for the “Type 2 Diabetes and Cardiovascular Disease Risk Management” interactive case study that allows you to follow a patient through key stages and decision points in her diabetes care. Claim your credits by completing the survey and posttest.

 

Incretins and Questions About the Pancreas

 
Over the past six months we have had more questions than answers about the risk of incretin therapy (DPP-4 inhibitors and GLP-1 agonists) and the increased risks for both pancreatitis and pancreatic carcinoma. The discussion seems to have resolved to an interim and perhaps temporary conclusion based on the recent American Diabetes Association Scientific Sessions in Chicago in June.
 
At that conference Dr.